FDA Gives Nod To Nasal Spray Migraine Treatment From Impel NeuroPharma; Stock Jumps

• The FDA has approved Impel NeuroPharma Inc's (NASDAQ: IMPL) Trudhesa (dihydroergotamine mesylate) nasal spray for the acute treatment of migraine with or without aura in adults.

• Using Impel's Precision Olfactory Delivery technology, Trudhesa gently delivers dihydroergotamine mesylate to the bloodstream through the vascular-rich upper nasal space.

• The commercial launch of Trudhesa is planned for early October 2021.

• In the STOP 301 study, 38% had pain freedom, 66% had pain relief, and 52% had freedom from their most bothersome migraine symptom two hours after their first dose of Trudhesa.

• In July, Impel NeuroPharma closed a million debt facility with Oxford Finance LLC and Silicon Valley Bank.

• Under the terms of the debt facility, the second tranche of $10 million is available upon the approval of Trudhesa.

• Related content: Benzinga's Full FDA Calendar.

• Price Action: IMPL stock traded higher at 50% at $34.68 during the premarket session on the last check Friday. Trading in IMPL shares was halted earlier.

See more from Benzinga

• Click here for options trades from Benzinga

• AstraZeneca's Ultomiris Scores European Nod For Rare Blood Disorder In Kids, Adolescents

• EMA Reviewing Cases Of Multisystem Inflammatory Syndrome After Pfizer COVID Shot

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.